NCT01362803 2026-03-02AZD6244 Hydrogen Sulfate for Children With Nervous System TumorsNational Institutes of Health Clinical Center (CC)Phase 1/2 Active not recruiting99 enrolled 3 FDA
NCT03363373 2026-02-19Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone MarrowY-mAbs TherapeuticsPhase 2 Recruiting122 enrolled 2 FDA